Novel peptide scaffold antifungal for pharma and crop
This technology covers a family of naturally derived cyclic peptide compounds that kill or inhibit fungi. The compounds were isolated, characterized, and formulated into pharmaceutical and agricultural compositions. They can be delivered through topical carriers like creams, ointments, and liposomes, making them suitable for treating fungal infections on skin or in clinical settings. The patent covers not just the compounds themselves but the methods of purifying them and their use in both human medicine and crop protection.
What you could build
A topical or agricultural antifungal product built on a proprietary peptide scaffold, sold to specialty pharma companies developing dermatological antifungals or to ag-biotech firms seeking novel crop protection actives.
Who in Virginia should care
Virginia-based pharmaceutical manufacturers, biotech startups in the Charlottesville or Northern Virginia corridor, or agricultural chemical companies with Virginia operations would be natural licensing candidates.
Readiness: Lab validated
Concept — described but not yet demonstrated. Lab validated — supported by experimental results in the patent. Prototype likely — the text describes a built, working embodiment.
Readiness is inferred from the patent text, not from a lab visit.
The record
- Inventors
- Eric W. Schmidt, Joseph O. Falkinham, Peter W. Jeffs
- Granted
- January 30, 2018
- Status
- Granted patent
- Patent number
- 9879048
Ready to talk?
Virginia Tech Intellectual Properties handles licensing for this technology.
Prosim summaries are generated from public patent text and are not legal advice.